Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.41 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.41 |
| ▸ | NRP1 | O14786 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615168 | 0.92 | GNRHR (0.45) | APLNRCAPN1NTSR2NTSR1 | |
| SCHEMBL14172897 | 0.92 | APLNR (0.43) | APLNRCAPN1NMUR2NMUR1OPRK1 | |
| SCHEMBL29383471 | 0.92 | GNRHR (0.45) | APLNRCAPN1NTSR2NTSR1 | |
| SCHEMBL30440642 | 0.87 | OPRM1 (0.47) | APLNRNMUR2NMUR1OPRK1 | |
| SCHEMBL30440639 | 0.87 | OPRM1 (0.47) | APLNRNMUR2NMUR1OPRK1 | |
| SCHEMBL29391291 | 0.85 | GNRHR (0.47) | NTSR2NTSR1OPRK1 | |
| Acetic Acid SCHEMBL30440885 | 0.84 | OPRM1 (0.48) | APLNRNMUR2NMUR1OPRK1 | |
| SCHEMBL28613560 | 0.83 | NTSR2 (0.39) | APLNRCAPN1NTSR2NTSR1NMUR2 | |
| SCHEMBL30440660 | 0.81 | OPRM1 (0.46) | NTSR2NTSR1NMUR2NMUR1OPRK1 | |
| SCHEMBL32670190 | 0.79 | OPRK1 (0.61) | NMUR2NMUR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129773-A1 | METHODS OF TREATING AUTISM AND AUTISM SPECTRUM DISORDERS | GEIER MARK R (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070254314-A1 | Methods of treating autism and autism spectrum disorders | GEIER, DAVID A. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254314-A1 | Methods of treating autism and autism spectrum disorders | SHBG, AS3MT, CYP21A2 | APLNR 542/4885CAPN1 1362/4885NTSR2 624/4885 |
| US-20120129773-A1 | METHODS OF TREATING AUTISM AND AUTISM SPECTRUM DISORDERS | SHBG, AS3MT, CYP21A2 | APLNR 542/4885CAPN1 1362/4885NTSR2 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.